Clinical Trial Update: The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global) [Phase 3]

View source ↗

Summary

This update describes a phase 3 trial evaluating 177Lu-TLX591 in combination with standard of care versus standard of care alone for metastatic castration-resis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• 177Lu-TLX591

Snippet

Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 3 | Status: RECRUITING